Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

BACKGROUND: MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but development of drug resistance within a median progression-free survival (PFS) of 9–12 months. Understanding mechanisms of resistance and identifying effective therapeutic alternati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Proteomics
Main Authors: Zila, Nina, Bileck, Andrea, Muqaku, Besnik, Janker, Lukas, Eichhoff, Ossia M., Cheng, Phil F., Dummer, Reinhard, Levesque, Mitchell P., Gerner, Christopher, Paulitschke, Verena
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844114/
https://ncbi.nlm.nih.gov/pubmed/29541007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12014-018-9189-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados